(Q36732058)

15 August 2017

Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient (English)

1 reference

15 August 2017

1 reference

1 reference

James H Doroshow

1

1 reference

PMCID

2435409

15 August 2017

Ralph E Parchment

series ordinal

2

1 reference

PMCID

2435409

15 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

15 August 2017

Clinical Cancer Research

1 reference

15 August 2017

14

1 reference

15 August 2017

12

1 reference

15 August 2017

3658-3663

1 reference

Phase 0 trials: an industry perspective

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Designing phase 0 cancer clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Innovative early development regulatory approaches: expIND, expCTA, microdosing

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Ethics at phase 0: clarifying the issues

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Trends in the use and role of biomarkers in phase I oncology trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Drug development in oncology: classical cytotoxics and molecularly targeted agents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Can the pharmaceutical industry reduce attrition rates?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

The ethics of phase 0 oncology trials

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Patient perspectives on phase 0 clinical trials

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Phase 0 trials: are they ethically challenged?

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Compressing drug development timelines in oncology using phase '0' trials.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Stability of phosphoprotein as a biological marker of tumor signaling

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Sugen falls as casualty of Pfizer-Pharmacia merger.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435409

Accelerated titration designs for phase I clinical trials in oncology

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18559579

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Unexplored pharmacokinetic opportunities with microdosing in oncology

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18559579

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-07-4562

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

PMCID

2435409